Does Cost-Effectiveness Analysis Really Need to Abandon the Incremental Cost-Effectiveness Ratio to Embrace Net Benefit?

Is it really possible to build a bridge between cost-benefit analysis and cost-effectiveness analysis?

Cost-benefit analysis (CBA) is a recognised as the economic evaluation technique that accords most with the underlying principles of standard welfare economic theory. However, due to problems associated with the technique, economists evaluating resources allocation decisions in health care have most often used cost-effective analysis (CEA), in which health benefits are expressed in non-monetary...

Incremental cost-effectiveness ratio and net monetary benefit: Current use in pharmacoeconomics and future perspectives.

In evaluating the cost/effectiveness of therapeutic interventions (e.g. those based on innovative drugs or on Class-III medical devices), two main pharmacoeconomic parameters have been used over the past decades: the incremental cost-effectiveness ratio (ICER [1–3]) and the net monetary benefit (NMB [4–6]). The ICER and the NMB share some common features because they both require a pre-defined ...

(Cost benefit analysis and cost−effectiveness analysis) Table of Contents

Incremental Cost-Effectiveness (ICE) Concepts

Furthering benefit/risk ratio and cost effectiveness of anticancer drugs.

BACKGROUND In Russia, the incidence of melanoma is increasing steadily. The approved standard of specialized medical care for melanoma of the skin defined the range of drugs, recommended for the provision of quality health care. However, it appears that the most effective innovative and safe medicines are at the same time the most expensive drugs. The most important is the assessment of drug us...